Differential modulation of human {beta}-defensins expression in human gingival epithelia by Porphyromonas gingivalis lipopolysaccharide with tetra- and penta-acylated lipid A structures.
Porphyromonas gingivalis lipopolysaccharide (LPS) is a crucial virulence factor strongly involved in the development of chronic periodontitis. It displays a significant amount of lipid A structural heterogeneity, containing both tetra- (LPS(1435/1449) ) and penta-acylated (LPS( 1690)) lipid A structures with opposing effects on E-selectin expression in human endothelial cells. Little is known about how these two isoforms of P. gingivalis LPS could differentially affect host innate immune responses in human gingival epithelia. The present study compares the modulatory effects of P. gingivalis LPS(1435/1449) and LPS(1690) on the expression of human beta-defensins (hBDs) in the reconstituted human gingival epithelium, and examines the involvements of a panel of pattern recognition receptors in the modulatory effects concerned. It is shown that hBD-1, hBD-2 and hBD-3 mRNAs are significantly up-regulated by P. gingivalis LPS(1690), but down-regulated by P. gingivalis LPS( 1435/1449). Toll-like receptor (TLR) 2 and CD14 mRNAs are also differentially regulated, and the modulation of hBD-2 expression may be through the co-operation of both TLR2 and TLR4. This study suggests that P. gingivalis LPS with different lipid A structures could differentially modulate host innate immune responses in human gingival epithelia, which may be a hitherto undescribed novel pathogenic mechanism of P. gingivalis in periodontal pathogenesis.
Lu
Qian
Q
The University of Hong Kong, Prince Philip Dental Hospital, Hong Kong.
Darveau
Richard P
RP
Samaranayake
Lakshman P
LP
Wang
Cun-Yu
CY
Jin
Lijian
L
D000215:Acylation; D016866:Bacteroidaceae Infections / Q000150:complications / Q000276:immunology; D055113:Chronic Periodontitis / Q000209:etiology / Q000276:immunology; D004848:Epithelium / Q000187:drug effects / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D005786:Gene Expression Regulation / Q000187:drug effects / Q000276:immunology; D005881:Gingiva / Q000473:pathology; D054884:Host-Pathogen Interactions; D006801:Humans; D007113:Immunity, Innate; D008050:Lipid A / Q000031:analogs & derivatives / Q000494:pharmacology*; D018950:Lipopolysaccharide Receptors / Q000096:biosynthesis / Q000235:genetics; D016966:Porphyromonas gingivalis / Q000276:immunology* / Q000472:pathogenicity; D051195:Toll-Like Receptor 2 / Q000096:biosynthesis* / Q000235:genetics; D051197:Toll-Like Receptor 4 / Q000096:biosynthesis / Q000235:genetics; D023083:beta-Defensins / Q000096:biosynthesis* / Q000235:genetics
D008050:Lipid A; D018950:Lipopolysaccharide Receptors; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D023083:beta-Defensins